Safety profile
Doptelet is well tolerated and the most frequently reported adverse reactions (≥1/10) were headache and fatigue6
In the Phase 3 study of adult patients with chronic ITP, exposure-adjusted adverse events of Doptelet were generally comparable with placebo:1
- Any TEAE: 4.3% per patient-week vs 6.6% with placebo
- Any SAE: 1.2% per patient-week vs 0.7% with placebo
Similar AE profiles were observed across multiple studies within ITP and chronic liver disease.1–5
Doptelet is the only oral TPO-RA that has not been associated with significant hepatotoxicity in clinical trials; no liver function monitoring is required.1,6
This table is drawn up by SOBI based on table IV p 488 in ref 2
Doptelet is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo aninvasive procedure. 6
Doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). 6
Monitoring and dose adjustment
After initiating therapy, assess platelet counts at least once weekly until a stable platelet count ≥ 50 × 109/L and ≤ 150 × 109/L has been achieved. Twice weekly platelet count monitoring should be conducted during the first weeks of therapy in patients receiving avatrombopag only once or twice weekly. Twice weekly monitoring should also be conducted after dose adjustments during the treatment. Due to the potential risk of platelet counts above 400 × 109/L within the first weeks of treatment patients should be carefully monitored for any signs or symptoms of thrombocytosis. After a stable platelet count has been achieved, obtain platelet counts at least monthly. After discontinuation of avatrombopag, platelet counts should be obtained weekly for at least 4 weeks.6
*Exposure-adjusted incidence rate = number of events/total patient-weeks exposure x 100%.1
AE, adverse event; ITP, immune thrombocytopenia; SAE, serious adverse event; TEAE, treatment-emergent adverse event; TPO-RA, thrombopoietin receptor agonist.
References
1. Jurczak W, Chojnowski K, Mayer J, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol. 2018;183(3):479-490. 2. Al-Samkari H, Jiang D, Gernsheimer T, et al. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study. Br J Haematol. 2022;197(3):359-366. 3. Bussel JB, Kuter DJ, Aledort LM, et al. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood. 2014;123(25):3887-3894. 4. Terrault N, Chen YC, Izumi N, et al. Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia. Gastroenterology. 2018;155(3):705-718. 5. Terrault NA, Hassanein T, Howell CD, et al. Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure. J Hepatol. 2014;61(6):1253-1259. 6. Doptelet Summary of Product Characteristics. 22/05/2025